From Biovotion to Biofourmis


The Zurich-based Biovotion, provider of a clinical-grade wearable biosensor platform is now a subsidiary of Biofourmis, the Boston based global leader in digital therapeutics. Following the acquisition, the entire startup team will be incorporated into the parent company under the new name Biofourmis AG based in Zurich.



Founded in 2011 in Zurich Biovotion has grown to become a wearable monitoring solutions provider. The company’s lead product is the clinical-grade Everion device, a multi-sensor platform worn on the arm for continuous monitoring. The Everion Remote Monitoring Solution is capable of non-invasively measuring 22 clinical parameters and multiple non-clinical parameters in real-time. The next generation of Everion is already under development and will have the ability to capture additional vital parameters, including continuous blood pressure trends. Following several years of collaboration with the Boston based digital therapeutics specialist Biofourmis, the latter announced that it has reached an agreement to acquire Biovotion in order to offer proprietary, clinical-grade wearables as part of its Biovitals ecosystem, a highly sophisticated personalized AI-powered predictive analytics platform that predicts clinical exacerbation in advance of a critical event. Clinical-grade wearables are becoming integral across all areas of healthcare, offering continuous real-time physiological data formerly only available in clinical settings. "Our relationship with Biofourmis has been extremely beneficial over the years and in that time has grown in scope and depth, so joining forces made strategic sense for both our companies," said Markus Christen, Biovotion Chairman and CEO. Thanks to the acquisition, the two platforms will complement each other to create a comprehensive digital therapeutics solution. The multi-parameter physiology data captured from Everion will be an integral component of Biovitals' digital therapeutics products and pipeline to manage conditions such as heart failure, COPD, oncology and pain. These products are tailored to help providers identify the best therapies for managing chronic conditions before patients' health worsens, potentially reducing hospital readmissions and decreasing the need for emergency department visits to reduce costs. "We are thrilled to add Everion to the Biovitals ecosystem, which will continue to help our clients achieve their goals such as demonstrating the value of pharmacotherapy, managing chronic diseases, predicting and preventing adverse events, and improving clinical outcomes—and ultimately reducing healthcare costs," said Kuldeep Singh Rajput, CEO and founder of Biofourmis. From Biovotion AG to Biofourmis AGThe entire Biovotion team will be incorporated into the Biofourmis family under the name "Biofourmis AG" in Zürich. The team brings deep knowledge and insights for developing and launching cutting-edge clinical-grade wearables, as well as an impressive roster of more than 80 current and previous partners—including large global pharmaceutical companies and contract research organizations (CROs), healthcare providers such as Mayo Clinic and the University Hospital of Basel, and technology partners such as IBM Research and Microsoft.(Press release/ran)